IT-901 is a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses. IT-901 potently inhibits the NF-κB subunit c-Rel. IT-901 suppressed graft-versus-host disease while preserving graft-versus-lymphoma activity during allogeneic transplantation. Further preclinical assessment of IT-901 for the treatment of human B-cell lymphoma revealed antitumor properties in vitro and in vivo without restriction to NF-κB-dependent lymphoma. IT-901 did not elicit increased levels of reactive oxygen species in normal leukocytes, illustrating its cancer selective properties. IT-901 is a novel therapeutic agent to treat human lymphoid tumors and ameliorate graft-versus-host disease.
MedKoo Cat#: 407414
Name: IT-901
CAS#: 1584121-99-2
Chemical Formula: C17H14N2O4S
Exact Mass: 342.0674
Molecular Weight: 342.37
Elemental Analysis: C, 59.64; H, 4.12; N, 8.18; O, 18.69; S, 9.36
| Solvent | mg/mL | mM | |
|---|---|---|---|
| Solubility | |||
| DMF | 33.0 | 96.39 | |
| DMSO | 33.0 | 96.39 | |
| DMSO:PBS (pH 7.2) (1:6) | 0.1 | 0.41 |
The following data is based on the product molecular weight 342.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
